588 related articles for article (PubMed ID: 22774396)
21. Effects of inositol on ovarian function and metabolic factors in women with PCOS: a randomized double blind placebo-controlled trial.
Gerli S; Mignosa M; Di Renzo GC
Eur Rev Med Pharmacol Sci; 2003; 7(6):151-9. PubMed ID: 15206484
[TBL] [Abstract][Full Text] [Related]
22. Potential role and therapeutic interests of myo-inositol in metabolic diseases.
Croze ML; Soulage CO
Biochimie; 2013 Oct; 95(10):1811-27. PubMed ID: 23764390
[TBL] [Abstract][Full Text] [Related]
23. Results from the International Consensus Conference on Myo-inositol and d-chiro-inositol in Obstetrics and Gynecology: the link between metabolic syndrome and PCOS.
Facchinetti F; Bizzarri M; Benvenga S; D'Anna R; Lanzone A; Soulage C; Di Renzo GC; Hod M; Cavalli P; Chiu TT; Kamenov ZA; Bevilacqua A; Carlomagno G; Gerli S; Oliva MM; Devroey P
Eur J Obstet Gynecol Reprod Biol; 2015 Dec; 195():72-76. PubMed ID: 26479434
[TBL] [Abstract][Full Text] [Related]
24. Comparison between effects of myo-inositol and D-chiro-inositol on ovarian function and metabolic factors in women with PCOS.
Pizzo A; Laganà AS; Barbaro L
Gynecol Endocrinol; 2014 Mar; 30(3):205-8. PubMed ID: 24351072
[TBL] [Abstract][Full Text] [Related]
25. d-chiro-Inositol and alpha lipoic acid treatment of metabolic and menses disorders in women with PCOS.
Cianci A; Panella M; Fichera M; Falduzzi C; Bartolo M; Caruso S
Gynecol Endocrinol; 2015 Jun; 31(6):483-6. PubMed ID: 25893270
[TBL] [Abstract][Full Text] [Related]
26. Metabolic and hormonal effects of a combined Myo-inositol and d-chiro-inositol therapy on patients with polycystic ovary syndrome (PCOS).
Januszewski M; Issat T; Jakimiuk AA; Santor-Zaczynska M; Jakimiuk AJ
Ginekol Pol; 2019; 90(1):7-10. PubMed ID: 30756365
[TBL] [Abstract][Full Text] [Related]
27. Efficacy of myo-inositol and d-chiro-inositol combination on menstrual cycle regulation and improving insulin resistance in young women with polycystic ovary syndrome: A randomized open-label study.
Kachhawa G; Senthil Kumar KV; Kulshrestha V; Khadgawat R; Mahey R; Bhatla N
Int J Gynaecol Obstet; 2022 Aug; 158(2):278-284. PubMed ID: 34624138
[TBL] [Abstract][Full Text] [Related]
28. The menstrual cycle regularization following D-chiro-inositol treatment in PCOS women: a retrospective study.
La Marca A; Grisendi V; Dondi G; Sighinolfi G; Cianci A
Gynecol Endocrinol; 2015 Jan; 31(1):52-6. PubMed ID: 25268566
[TBL] [Abstract][Full Text] [Related]
29. Inositol in Polycystic Ovary Syndrome: Restoring Fertility through a Pathophysiology-Based Approach.
Laganà AS; Garzon S; Casarin J; Franchi M; Ghezzi F
Trends Endocrinol Metab; 2018 Nov; 29(11):768-780. PubMed ID: 30270194
[TBL] [Abstract][Full Text] [Related]
30. Inositol's and other nutraceuticals' synergistic actions counteract insulin resistance in polycystic ovarian syndrome and metabolic syndrome: state-of-the-art and future perspectives.
Paul C; Laganà AS; Maniglio P; Triolo O; Brady DM
Gynecol Endocrinol; 2016 Jun; 32(6):431-8. PubMed ID: 26927948
[TBL] [Abstract][Full Text] [Related]
31. Hyperinsulinemia is closely related to low urinary clearance of D-chiro-inositol in men with a wide range of insulin sensitivity.
Villeneuve MC; Ostlund RE; Baillargeon JP
Metabolism; 2009 Jan; 58(1):62-8. PubMed ID: 19059532
[TBL] [Abstract][Full Text] [Related]
32. Inositol as putative integrative treatment for PCOS.
Genazzani AD
Reprod Biomed Online; 2016 Dec; 33(6):770-780. PubMed ID: 27717596
[TBL] [Abstract][Full Text] [Related]
33. Comparative efficacy of oral insulin sensitizers metformin, thiazolidinediones, inositol, and berberine in improving endocrine and metabolic profiles in women with PCOS: a network meta-analysis.
Zhao H; Xing C; Zhang J; He B
Reprod Health; 2021 Aug; 18(1):171. PubMed ID: 34407851
[TBL] [Abstract][Full Text] [Related]
34. Inositols in Polycystic Ovary Syndrome: An Overview on the Advances.
Facchinetti F; Unfer V; Dewailly D; Kamenov ZA; Diamanti-Kandarakis E; Laganà AS; Nestler JE; Soulage CO;
Trends Endocrinol Metab; 2020 Jun; 31(6):435-447. PubMed ID: 32396844
[TBL] [Abstract][Full Text] [Related]
35. D-Chiro-inositol and its significance in polycystic ovary syndrome: a systematic review.
Galazis N; Galazi M; Atiomo W
Gynecol Endocrinol; 2011 Apr; 27(4):256-62. PubMed ID: 21142777
[TBL] [Abstract][Full Text] [Related]
36. Effect of myo-inositol and melatonin versus myo-inositol, in a randomized controlled trial, for improving in vitro fertilization of patients with polycystic ovarian syndrome.
Pacchiarotti A; Carlomagno G; Antonini G; Pacchiarotti A
Gynecol Endocrinol; 2016; 32(1):69-73. PubMed ID: 26507336
[TBL] [Abstract][Full Text] [Related]
37. Differential insulin response to oral glucose tolerance test (OGTT) in overweight/obese polycystic ovary syndrome patients undergoing to myo-inositol (MYO), alpha lipoic acid (ALA), or combination of both.
Genazzani AD; Prati A; Marchini F; Petrillo T; Napolitano A; Simoncini T
Gynecol Endocrinol; 2019 Dec; 35(12):1088-1093. PubMed ID: 31304823
[TBL] [Abstract][Full Text] [Related]
38. Inositols in PCOS.
Kamenov Z; Gateva A
Molecules; 2020 Nov; 25(23):. PubMed ID: 33260918
[TBL] [Abstract][Full Text] [Related]
39. The influence of different inositol stereoisomers supplementation in pregnancy on maternal gestational diabetes mellitus and fetal outcomes in high-risk patients: a randomized controlled trial.
Celentano C; Matarrelli B; Pavone G; Vitacolonna E; Mattei PA; Berghella V; Liberati M
J Matern Fetal Neonatal Med; 2020 Mar; 33(5):743-751. PubMed ID: 30558466
[No Abstract] [Full Text] [Related]
40. Ovulatory and metabolic effects of D-chiro-inositol in the polycystic ovary syndrome.
Nestler JE; Jakubowicz DJ; Reamer P; Gunn RD; Allan G
N Engl J Med; 1999 Apr; 340(17):1314-20. PubMed ID: 10219066
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
